

Fredrik J Swartling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6444134/publications.pdf>

Version: 2024-02-01

50
papers

2,417
citations

257450

24
h-index

214800

47
g-index

52
all docs

52
docs citations

52
times ranked

4368
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas. <i>Neuro-Oncology</i> , 2023, 25, 97-107.	1.2	3
2	Profiling chromatin accessibility in formalin-fixed paraffin-embedded samples. <i>Genome Research</i> , 2022, 32, 150-161.	5.5	16
3	Basal cell carcinomas acquire secondary mutations to overcome dormancy and progress from microscopic to macroscopic disease. <i>Cell Reports</i> , 2022, 39, 110779.	6.4	4
4	Photophysical characterization and fluorescence cell imaging applications of 4- <i>N</i> -substituted benzothiadiazoles. <i>RSC Advances</i> , 2022, 12, 14544-14550.	3.6	3
5	Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions. <i>Cancers</i> , 2022, 14, 3225.	3.7	2
6	The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2. <i>Cancer Research</i> , 2021, 81, 2101-2115.	0.9	25
7	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. , 2021, 9, e002181.		42
8	SOX9 Defines Distinct Populations of Cells in SHH Medulloblastoma but Is Not Required for Math1-Driven Tumor Formation. <i>Molecular Cancer Research</i> , 2021, 19, 1831-1839.	3.4	5
9	Indolylbenzothiadiazoles as highly tunable fluorophores for imaging lipid droplet accumulation in astrocytes and glioblastoma cells. <i>RSC Advances</i> , 2021, 11, 23960-23967.	3.6	3
10	Medulloblastomics revisited: biological and clinical insights from thousands of patients. <i>Nature Reviews Cancer</i> , 2020, 20, 42-56.	28.4	147
11	A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. <i>Cell Reports</i> , 2020, 32, 107897.	6.4	41
12	Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20127-20138.	7.1	23
13	Perturbation-based gene regulatory network inference to unravel oncogenic mechanisms. <i>Scientific Reports</i> , 2020, 10, 14149.	3.3	4
14	Nuclear Receptor Binding Protein 2 Is Downregulated in Medulloblastoma, and Reduces Tumor Cell Survival upon Overexpression. <i>Cancers</i> , 2020, 12, 1483.	3.7	6
15	Targeting MYCN in Molecularly Defined Malignant Brain Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 626751.	2.8	18
16	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019, 25, 433-446.e7.	11.1	56
17	Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes. <i>Bioinformatics</i> , 2019, 35, 3357-3364.	4.1	34
18	Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. <i>Cell Stem Cell</i> , 2019, 25, 855-870.e11.	11.1	38

#	ARTICLE	IF	CITATIONS
19	BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. <i>Cell Death and Disease</i> , 2019, 10, 881.	6.3	26
20	LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients. <i>Journal of Pathology</i> , 2019, 247, 228-240.	4.5	19
21	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. <i>Oncogene</i> , 2018, 37, 2850-2862.	5.9	71
22	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-OTX2-SNAIL via PTEN inhibition. <i>Brain</i> , 2018, 141, 1300-1319.	7.6	22
23	Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. <i>Nature Communications</i> , 2018, 9, 4121.	12.8	36
24	Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. <i>IScience</i> , 2018, 9, 71-83.	4.1	38
25	MBRS-42. GMYC: A NOVEL INDUCIBLE TRANSGENIC MODEL OF GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i137-i137.	1.2	1
26	Loss of Conservation of Graph Centralities in Reverse-engineered Transcriptional Regulatory Networks. <i>Methodology and Computing in Applied Probability</i> , 2017, 19, 1089-1105.	1.2	1
27	Comparing the landscapes of common retroviral insertion sites across tumor models. <i>AIP Conference Proceedings</i> , 2017, , .	0.4	2
28	Targeting SOX9 for degradation to inhibit chemoresistance, metastatic spread, and recurrence. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1252871.	0.7	6
29	Medulloblastoma: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 134, 679-689.	7.7	25
30	Mouse Models of Pediatric Supratentorial High-grade Glioma Reveal How Cell-of-Origin Influences Tumor Development and Phenotype. <i>Cancer Research</i> , 2017, 77, 802-812.	0.9	15
31	Modeling and Targeting MYC Genes in Childhood Brain Tumors. <i>Genes</i> , 2017, 8, 107.	2.4	22
32	Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential. <i>Frontiers in Oncology</i> , 2017, 7, 115.	2.8	10
33	Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression. <i>Oncotarget</i> , 2017, 8, 24815-24827.	1.8	42
34	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. <i>EMBO Journal</i> , 2016, 35, 2192-2212.	7.8	58
35	Utilizing the Dog Genome in the Search for Novel Candidate Genes Involved in Glioma Development—Genome Wide Association Mapping followed by Targeted Massive Parallel Sequencing Identifies a Strongly Associated Locus. <i>PLoS Genetics</i> , 2016, 12, e1006000.	3.5	54
36	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. <i>Cancer Cell</i> , 2015, 27, 72-84.	16.8	165

#	ARTICLE	IF	CITATIONS
37	Deregulated proliferation and differentiation in brain tumors. <i>Cell and Tissue Research</i> , 2015, 359, 225-254.	2.9	28
38	Signals that regulate the oncogenic fate of neural stem cells and progenitors. <i>Experimental Neurology</i> , 2014, 260, 56-68.	4.1	15
39	Oncoprotein stabilization in brain tumors. <i>Oncogene</i> , 2014, 33, 4709-4721.	5.9	15
40	BET Bromodomain Inhibition of <i>MYC</i> -Amplified Medulloblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 912-925.	7.0	296
41	What underlies the diversity of brain tumors?. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 5-24.	5.9	16
42	Myc proteins in brain tumor development and maintenance. <i>Upsala Journal of Medical Sciences</i> , 2012, 117, 122-131.	0.9	31
43	miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma. <i>BMC Cancer</i> , 2012, 12, 378.	2.6	41
44	Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. <i>Cancer Cell</i> , 2012, 21, 601-613.	16.8	177
45	Non-Stem Cell Origin for Oligodendroglioma. <i>Cancer Cell</i> , 2010, 18, 669-682.	16.8	211
46	Pleiotropic role for <i>MYCN</i> in medulloblastoma. <i>Genes and Development</i> , 2010, 24, 1059-1072.	5.9	146
47	Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. <i>Oncogene</i> , 2009, 28, 3121-3131.	5.9	87
48	Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. <i>Oncogene</i> , 2005, 24, 3896-3905.	5.9	67
49	Cell Type-Specific Tumor Suppression by Ink4a and Arf in Kras-Induced Mouse Gliomagenesis. <i>Cancer Research</i> , 2005, 65, 2065-2069.	0.9	91
50	Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11334-11337.	7.1	111